Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties.

Cultures of primary hepatocytes and hepatoma cell line HepG2 are frequently used in in vitro models for human biotransformation studies. In this study, we characterized and compared the capacity of these model systems to indicate the presence of different classes of promutagens. Genotoxic sensitivity, enzyme activity, and gene expression were monitored in response to treatment with food promutagens benzo[a]pyrene, dimethylnitrosamine (DMN), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). DNA damage could be detected reliably with the comet assay in primary human hepatocytes, which were maintained in sandwich culture. All three promutagens caused DNA damage in primary cells, but in HepG2 no genotoxic effects of DMN and PhIP could be detected. We supposed that the lack of specific enzymes accounts for their inability to process these promutagens. Therefore, we quantified the expression of a broad range of genes coding for drug-metabolizing enzymes with real-time reverse transcription-polymerase chain reaction. The genes code for cytochromes p450 and, in addition, for a series of important phase II enzymes. The expression level of these genes in human hepatocytes was similar to those previously reported for human liver samples. On the other hand, expression levels in HepG2 differed significantly from that in human. Activity and expression, especially of phase I enzymes, were demonstrated to be extremely low in HepG2 cells. Up-regulation of specific genes by test substances was similar in both cell types. In conclusion, human hepatocytes are the preferred model for biotransformation in human liver, whereas HepG2 cells may be useful to study regulation of drug-metabolizing enzymes.

[1]  国崎 直道,et al.  N-Nitrosodimethylamine. , 2019, Report on carcinogens : carcinogen profiles.

[2]  D. G. McCarver,et al.  The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. , 2002, The Journal of pharmacology and experimental therapeutics.

[3]  R. Edwards,et al.  Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  S. Safe,et al.  Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. , 2001, Biochemical pharmacology.

[5]  J. Castell,et al.  Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus‐mediated antisense targeting , 2001, Hepatology.

[6]  A. Cederbaum,et al.  Adenovirus-mediated Overexpression of Catalase in the Cytosolic or Mitochondrial Compartment Protects against Cytochrome P450 2E1-dependent Toxicity in HepG2 Cells* , 2001, The Journal of Biological Chemistry.

[7]  Chunja Lee,et al.  The human cytochrome P450 1A1 mRNA is rapidly degraded in HepG2 cells. , 2000, Archives of biochemistry and biophysics.

[8]  A Orimo,et al.  Molecular cloning of ring finger protein 21 (RNF21)/interferon-responsive finger protein (ifp1), which possesses two RING-B box-coiled coil domains in tandem. , 2000, Genomics.

[9]  J. Warrington,et al.  Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. , 2000, Physiological genomics.

[10]  M. Burke,et al.  Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. , 2000, Toxicology.

[11]  C. Rodríguez-Antona,et al.  Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. , 2000, Archives of biochemistry and biophysics.

[12]  A. Deiwick,et al.  The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat , 1999, Nature Medicine.

[13]  C. Helma,et al.  Single-cell gel electrophoresis assays with human-derived hepatoma (Hep G2) cells. , 1999, Mutation research.

[14]  M. Knize,et al.  Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. , 1999, Advances in experimental medicine and biology.

[15]  P. Strickland,et al.  Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. , 1998, Carcinogenesis.

[16]  P. Hrelia,et al.  The pitfall of detoxifying enzymes. , 1998, Mutation research.

[17]  F. Farin,et al.  Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR. , 1998, DNA and cell biology.

[18]  M. Manns,et al.  Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. , 1997, Molecular pharmacology.

[19]  K. Imaida,et al.  Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat. , 1997, Mutation research.

[20]  P. Beaune,et al.  Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast. , 1996, Pharmacogenetics.

[21]  P. Knekt,et al.  Dietary intakes of nitrate, nitrite and NDMA in the Finnish Mobile Clinic Health Examination Survey. , 1996, Food additives and contaminants.

[22]  T Sakaki,et al.  Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. , 1996, Biochemical pharmacology.

[23]  H. Autrup,et al.  Autoregulation of human CYP1A1 gene promotor activity in HepG2 and MCF-7 cells. , 1996, Carcinogenesis.

[24]  H. Yamazaki,et al.  7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. , 1996, Biochemical pharmacology.

[25]  U. Christians,et al.  Use of organotypical cultures of primary hepatocytes to analyse drug biotransformation in man and animals. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  J. Schuetz,et al.  Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. , 1994, Pharmacogenetics.

[27]  J V Castell,et al.  A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. , 1993, Analytical biochemistry.

[28]  Mehmet Toner,et al.  A Stable Long‐Term Hepatocyte Culture System for Studies of Physiologic Processes: Cytokine Stimulation of the Acute Phase Response in Rat and Human Hepatocytes , 1992, Biotechnology progress.

[29]  P. Workman,et al.  DT-diaphorase and cancer chemotherapy. , 1992, Biochemical pharmacology.

[30]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[31]  U. Schibler,et al.  A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the sam mRNA , 1991, Cell.

[32]  A. Natarajan,et al.  Use of human hepatoma cells for in vitro metabolic activation of chemical mutagens/carcinogens. , 1991, Mutagenesis.

[33]  D. Grant,et al.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. , 1990, DNA and cell biology.

[34]  R. Tompkins,et al.  Hepatocyte function and extracellular matrix geometry: long‐term culture in a sandwich configuration , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  R. Tice,et al.  A simple technique for quantitation of low levels of DNA damage in individual cells. , 1988, Experimental cell research.

[36]  J. Mathis,et al.  Drug metabolism by isolated fetal human hepatocytes in suspension and primary culture. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[37]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[38]  P. Seglen.  Preparation of isolated rat liver cells. , 1976, Methods in cell biology.

[39]  John Doull,et al.  VIRAL DISEASES: A SYMPOSIUM , 1976, The Ulster Medical Journal.

[40]  A. Hewer,et al.  Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide , 1974, Nature.

[41]  Jonathan Bard,et al.  COLLAGEN SUBSTRATA FOR STUDIES ON CELL BEHAVIOR , 1972, The Journal of cell biology.